| 臺大學術典藏 |
2022-08-19T00:20:56Z |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression
|
Yeh K.-H.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Shen Y.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.; Chang D.-Y.; Hu F.-C.; Shao Y.-Y.; CHIUN HSU; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
|
Cheng A.-L.; Meng R.; Chao Y.; Hsieh T.-Y.; Huang W.-T.; Hwang W.-S.; Yu C.-W.; Hsieh R.-K.; Huo T.-I.; Yang T.-S.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:57Z |
A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regression
|
Shen Y.-C.; CHIUN HSU; Cheng C.-C.; Hu F.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; CHIUN HSU; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:58Z |
Antiangiogenic strategies for the treatment of hepatocellular carcinoma
|
CHIUN HSU; Shen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:59Z |
Increased expression of 14-3-3�] promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma
|
Shen T.-L.; Lee Y.-M.; Chen P.-F.; Wang J.; Shyue S.-K.; Liou J.-Y.; CHIUN HSU; Liang S.-M.; Hung Y.-L.; Chen S.-C.; Jan Y.-J.; Ko B.-S.; Liu T.-A. |
| 臺大學術典藏 |
2022-08-19T00:20:59Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Lu Y.S.; Cheng A.L.; Kuo W.H.; Chen I.C.; Lin C.H.; Huang C.S.; Lien H.C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:21:00Z |
Overexpression of 14-3-3�` predicts tumour metastasis and poor survival in hepatocellular carcinoma
|
Liou J.-Y.; Ko B.-S.; Chang T.-C.; CHIUN HSU; Chen Y.-C.; Shen T.-L.; Chen S.-C.; Wang J.; Wu K.K.; Jan Y.-J. |
| 臺大學術典藏 |
2022-08-19T00:21:00Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Hsu C.-H.; Hu F.-C.; CHIUN HSU; Yu C.-W.; Shen Y.-C.; Hsu C.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:01Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Shao Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:02Z |
Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma
|
Whang-Peng J.; Cheng A.-L.; CHIUN HSU; Chen C.-M. |
| 臺大學術典藏 |
2022-08-19T00:21:02Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H.; Chang K.-J.; Kuo W.-H.; CHIUN HSU; Lee W.-C.; Liau J.-Y.; Huang C.-S.; Lu Y.-S.; Shao Y.-Y.; Kuo K.-T.; Hu F.-C. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion
|
Chen P.-J.; Furuse J.; Han K.-H.; CHIUN HSU; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. |
| 臺大學術典藏 |
2022-08-19T00:21:03Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Cheng A.-L.; Ding Y.-H.; CHIUN HSU; Shao Y.-Y.; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:04Z |
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B
|
Liou J.-Y.; Shyue S.-K.; Chang C.-C.; Golubovskaya V.M.; Shen T.-L.; Shen Y.-C.; CHIUN HSU; Kuo C.-C.; Ko B.-S.; Chang T.-C.; Chen C.-H.; Liu C.-C. |
| 臺大學術典藏 |
2022-08-19T00:21:04Z |
Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design
|
CHIUN HSU; Shen Y.-C.; Cheng C.-C.; Hu F.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:04Z |
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma
|
Jan Y.-J.; Ko B.-S.; CHIUN HSU; Chang T.-C.; Chen S.-C.; Wang J.; Liou J.-Y. |
| 臺大學術典藏 |
2022-08-19T00:21:04Z |
Sorafenib for the treatment of hepatocellular carcinoma across geographic regions
|
CHIUN HSU; Shen Y.-C.; Cheng A.L. |
| 臺大學術典藏 |
2022-08-19T00:21:05Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; CHIUN HSU; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:05Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Cheng A.-L.; CHIUN HSU; Wang D.-S.; Lu Y.-S.; Fan H.-H.; Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:06Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; CHIUN HSU; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
CHIUN HSU; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer
|
Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; CHIUN HSU; Liang P.-C.; Tsao P.-N.; Jan I.-S.; Wong J.-M. |
| 臺大學術典藏 |
2022-08-19T00:21:07Z |
Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma
|
Hsiao S.-M.; Chen C.-A.; CHIUN HSU; Lin H.-H.; Hsieh C.-Y.; Wei L.-H. |
